title: [Treatment of acute peptic gastroduodenal ulcer: omeprazole is superior to ranitidine especially in the early phase of ulcer healing. A prospective controlled randomized serial endoscopy study].
abstract: Omeprazole (OM) has been shown to be superior to H2-Blockers in terms of complete healing rates of gastric (GU) and duodenal ulcers (DU). We investigated in more detail the kinetics of ulcer healing under OM (20 mg mane) compared with ranitidine (RAN 300 mg nocte) in GU (n = 28) and DU (n = 27) by multiple series endoscopy. After endoscopic diagnosis (day 0) patients were allocated to either OM or RAN in a random order. Endoscopic controls were undertaken at day (d) 3, 7, 14, 21, 28, 42 up to complete ulcer healing. The seize of ulcer areas was assessed by independent endocopists estimating the longest and shortest diameter D acc. to the formula A = pi x D1 x D2:4.
  
  
  RESULTS
  In GU and DU cumulating healing rates were sign, higher under OM. In GU and DU, the most striking differences in the absolute and percentual reduction of ulcer seize in favour of OM vs RAN were observed mainly during the first week. At d3 under OM the reduction in DU-area was 43% and at d7 75% compared to a distinctly lower rate under RAN with the corresponding figures of 9% and 61% resp. In GU the mean reduction in area was for IM at d3 41%, at d7 82% in contrast to RAN at d3 of 34% and d7 of 49%. The faster healing during the first week was accompanied by sign more rapid reduction in day-and-night-painscore during OM vs RAN.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Klinik für Gastroenterologie, Allgemeines Krankenhaus, Celle.
authors.forename: J
authors.initials: J
authors.lastname: Hotz
authors.forename: W
authors.initials: W
authors.lastname: Kark
authors.forename: K
authors.initials: K
authors.lastname: Plein
authors.forename: F
authors.initials: F
authors.lastname: Wiedbrauck
authors.forename: A
authors.initials: A
authors.lastname: Guthke
authors.forename: O
authors.initials: O
authors.lastname: Otten
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016145:Endoscopy, Digestive System; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy*; D011446:Prospective Studies; D011899:Ranitidine / Q000009:adverse effects / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000897:Anti-Ulcer Agents; D011899:Ranitidine; D009853:Omeprazole
vernacular_title: Behandlung des akuten peptischen Gastroduodenal-Ulkus: Omeprazol ist Ranitidin besonders in der Frühphase der Ulkusheilung überlegen. Eine prospektive kontrollierte randomisierte Serien-Endoskopie-Studie.